The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Abstract
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.Methods In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136.Findings Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10·8 months (95% CI 10·0-12·0) in the afatinib group and 12·0 months (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74). Median progression-free survival was longer in the afatinib group (3·3 months, 95% CI 2·79-4·40) than it was in the placebo group (1·1 months, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group.Interpretation Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.Funding Boehringer Ingelheim Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, as monotherapy, they have failed to overcome T790M-mediated resistance in patients (28, 29), because concentrations at which these irreversible TKIs overcome T790M activity pre-clinically are not achievable in humans due to dose-limiting toxicity related to non-selective inhibition of wild-type EGFR (30).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [28]
In the citing paper
“However, we know from clinical experience that afatinib is unable to inhibit T790M in the clinic due to a lack of a therapeutic window”
In the citing paper
“For example, studies of afatinib monotherapy showed a response rate of less than 10% among patients with acquired resistance to erlotinib or gefitinib, with a progression-free survival of approximately 4 months.13,15”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [13]
In the citing paper
“However, in lung cancer patients, afatinib is only effective in EGFR TKI naive EGFR mutant cancers and has a RR of < 10% in patients with NSCLC that have developed resistance to gefitinib or erlotinib (13).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [13]
In the citing paper
“neither Afatinib [76] nor Neratinib [77] nor Dacomitinib [78] demonstrated significant activity as single agent in patients harboring the T790M mutations.”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [76]
In the citing paper
“However, for EGFR T790M mutated lung cancer, it failed to overcome EGFR T790M-mediated resistance in patients [36, 37].”
In the citing paper
“Sixty-three percent of the patients in the afatinib group and 76% in the control group received ≥ one subsequent regimen (all mutation statuses).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Response rate was 7% versus 0.5%.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“In a prespecified analysis, participants with a complete or partial response to a first-line EGFR TKI whose tumors also had known EGFR mutation test results (58 [88%] of 66), the HR for PFS was significant (0.23), but the HR for OS was not (0.90) in the afatinib arm.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Some of the second-line studies included patients who had received > two previous regimens.15,23,47,48,51,65”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“The study found no improvement in the primary end point of OS between patients randomly assigned to afatinib and those randomly assigned to placebo, although PFS was longer in the afatinib group (3.3 v 1.1 months; HR, 0.38; 95% CI, 0.31 to 0.48; P < .001).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Among these 96 patients, PFS was 3.3 months for those who received afatinib and 1.0 month for those who received placebo (HR, 0.55; 95% CI, 0.31 to 0.85; P = .009).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Self-citationRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Research works printed but not linked: 2
- Hirsh, 2011, Symptom and health-related quality of life benefit from afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase III study (LUX-Lung 1), Proc World Conf Lung Cancer
- Atagi, 2011, LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib, Proc World Conf Lung Cancer
Cited by
Sorted by citations
Items 601–700 of 988
Zhang, X., Ran, Y.-G., & Wang, K. (2016) · Future Oncology · doi:10.2217/fon-2016-0180 · Cited by 11
Zhao, X., Wu, X., Yu, W. J., Cai, X., Liu, Q., Fu, X., Liu, Z., Hu, D., Pan, S.-Y., & Huang, Q. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5869 · Cited by 11
Günther, M., Laux, J., & Laufer, S. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.11.021 · Cited by 11
Tien, Y., Tsai, C., Hou, W., Chiang, Y., Hsu, F., Tsai, Y., & Cheng, J. C. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01493-8 · Cited by 11
Wang, H., Wang, X., Xu, L., Cao, H., & Zhang, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4386 · Cited by 11
Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
Aredo, J. V., Wakelee, H. A., Neal, J. W., & Padda, S. K. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100497 · Cited by 11
Chu, Q. S.-C., Sangha, R. S., Hotte, S. J., Sergenson, G., Schnell, D., Chand, V. K., & Hirte, H. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0139-9 · Cited by 11
Hennessy, E. J., Chuaqui, C. E., Ashton, S. E., Colclough, N., Cross, D. A. E., Debreczeni, J. E., Eberlein, C., Gingipalli, L., Klinowska, T. C. M., Orme, J. P., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00058 · Cited by 11
Akher, F. B., Farrokhzadeh, A., Ravenscroft, N., & Kuttel, M. M. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c03440 · Cited by 11
Hsu, C., Yang, A. Y.-P., Chen, J.-Y., Tsai, H.-H., Lin, S.-H., Tai, P.-C., Huang, M.-H., Hsu, W.-H., Lin, A. M.-Y., & Yang, J. C. (2021) · Cancers · doi:10.3390/cancers13020272 · Cited by 10
Self-citationWu, C., Zhong, R., Wei, T., Jin, Y., He, C., Li, H., & Cheng, Y. (2024) · Oncology Letters · doi:10.3892/ol.2024.14431 · Cited by 13
Zhang, J., He, P., Wang, W., Wang, Y., Yang, H., Hu, Z., Song, Y., Chang, J., & Yu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00267 · Cited by 10
Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
Albalawi, F. S., Bhat, M. A., Bakheit, A. H. H., Rahman, A. F. M. M., Alsaif, N. A., Jones, A. M., & Romero‐Canelón, I. (2025) · Pharmaceuticals · doi:10.3390/ph18071051 · Cited by 10
Dacomitinib for the Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer
Mok, T. S. K., Lee, K., Tang, M., & Leung, L. K. S. (2014) · Future Oncology · doi:10.2217/fon.14.22 · Cited by 10
Mariano, C. J., Bosdet, I., Karsan, A., Ionescu, D. N., Murray, N., Laskin, J. J., Zhai, Y., Melosky, B. L., Sun, S. B., & Ho, C. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.007 · Cited by 10
Ahmad, H., Berzin, T. M., Yu, H. J., Huang, C. S., & Mishkin, D. S. (2014) · Gastroenterology report · doi:10.1093/gastro/gou033 · Cited by 10
Oda, N., Ichihara, E., Hotta, K., Ninomiya, K., Ninomiya, T., Kubo, T., Minami, D., Murakami, T., Yokoyama, T., Harada, D., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.07.003 · Cited by 10
Kazaz, S. N., & Öztop, İ. (2017) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2017.16042 · Cited by 10
Xie, J., Wang, X., Ge, H., Peng, F., Zheng, N., Wang, Q., & Tao, L. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28881 · Cited by 10
Haddad, R. I., Guigay, J., Keilholz, U., Clément, P. M., Fayette, J., Viana, L. D. S., Rolland, F., Cupissol, D., Geoffrois, L., Kornek, G. V., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.08.004 · Cited by 10
Kaur, G., Doroshow, J. H., & Teicher, B. A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100463 · Cited by 10
Shang, J., Zhou, L., Huang, L., Yang, F., Liu, Y., Zhang, C., Zu, L., Fan, R., Zhang, X., Liu, Y., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069645 · Cited by 10
Li, D., Chen, T., & Li, Q. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02410-x · Cited by 10
Santarpía, M., Pas, T. M. D., Altavilla, G., Spaggiari, L., & Rosell, R. (2013) · Future Oncology · doi:10.2217/fon.13.6 · Cited by 11
He, B., Xu, Y., Ding, V. W., Zhang, H., Zhang, X., & Jablons, D. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s92996 · Cited by 13
Zhang, Y., Chen, G., Chen, X., Fang, W., Gao, F., Yang, Y., Zhao, Y., Ma, Y., Hong, S., Zhang, Z., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19867 · Cited by 10
Self-citationOvercoming resistance in non‐small‐cell lung cancer: A practical lesson for the medicinal chemist
Ribaudo, G., Zanforlin, E., & Zagotto, G. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800037 · Cited by 10
Fu, J., Wan, Y., Huang, T., Wu, C., Liu, Y., Hsieh, M., Wu, Y., & Wu, C.-Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206386 · Cited by 10
Ding, L., Song, Z., Dong, B., Song, W., Cheng, C., Zhang, Y., & Zhang, W. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13489 · Cited by 10
Workman, P., & Collins, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00001-2 · Cited by 10
Gordon, M. S., Springett, G. M., Su, Y. B., Ould-Kaci, M., Wind, S., Zhao, Y., & LoRusso, P. M. (2015) · Future Oncology · doi:10.2217/fon.15.50 · Cited by 10
Her-2 targeting in uterine papillary serous carcinoma
Talwar, S., & Cohen, S. (2012) · Gynecologic Oncology Case Reports · doi:10.1016/j.gynor.2012.05.003 · Cited by 10
Deploying Ibrutinib to Lung Cancer: Another Step in the Quest Towards Drug Repurposing
Haura, E. B., & Rix, U. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju250 · Cited by 10
Uemura, I., Takahashi‐Suzuki, N., Kita, F., Kobayashi, M., Yamada, T., Iseki, K., & Satoh, T. K. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00672 · Cited by 8
Mapping cellular targets of covalent cancer drugs in the entire mammalian body
Pang, Z., Leung, V. H., Wang, C. C., Attarpour, A., Rinaldi, A., Shen, H., Moya-Garzón, M. D., Sigua, L. H., Rammel, C., Selke, A., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.030 · Cited by 9
Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond
Rajan, A., & Schrump, D. S. (2015) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2015.04.002 · Cited by 9
Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers
Eccles, S. A. (2012) · Frontiers in bioscience · doi:10.2741/4118 · Cited by 9
Qi, W., Tang, L., He, A., Yao, Y., & Shen, Z. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.06.005 · Cited by 9
Noda, S., & Kanda, S. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1164603 · Cited by 10
Remón, J., & Besse, B. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000081 · Cited by 9
Lu, X., Sang, D., Zhang, Y., & Yuan, Q. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100123 · Cited by 9
Burotto, M., Ali, S. A., & Coyne, G. O. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.973400 · Cited by 9
Genova, C., Rijavec, E., Biello, F., Rossi, G., Barletta, G., Bello, M. G. D., Vanni, I., Coco, S., Alama, A., & Grossi, F. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1261109 · Cited by 9
Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers
Alshareef, A. (2017) · Cancers · doi:10.3390/cancers9110148 · Cited by 10
de Mello, R. A., Escriu, C., Castelo‐Branco, P., Cabral, P. L., Mountzios, G., Lopes, G. D. L., Jr., & Madureira, P. (2017) · Oncotarget · doi:10.18632/oncotarget.23668 · Cited by 9
Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung
Chaikuad, A., Koch, P., Laufer, S., & Knapp, S. (2017) · Angewandte Chemie · doi:10.1002/ange.201707875 · Cited by 9
Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors
Camidge, D. R., Sequist, L. V. D., Janne, P. A., Weickhardt, A. J., Dowling, E. S., Alicea, J., Fan, J., & Oxnard, G. R. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.015 · Cited by 9
Modeling Exposure‐Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib
Niebecker, R., Maas, H. J., Staab, A., Freiwald, M., & Karlsson, M. O. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12384 · Cited by 9
Maarof, N. N. N., Alsalahi, A., Abdulmalek, E., Fakurazi, S., Tejo, B. A., & Rahman, M. B. A. (2021) · Cancers · doi:10.3390/cancers13040688 · Cited by 9
Non–Small-Cell Lung Cancer: Real-World Cost Consequence Analysis
Buja, A., Pasello, G., Luca, G. D., Bortolami, A., Zorzi, M., Rea, F., Pinato, C., Cin, A. D., Polo, A. D., Schiavon, M., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00863 · Cited by 9
Hopkins, A. M., Nguyen, A. M., Karapetis, C. S., Rowland, A., & Sorich, M. J. (2018) · Cancers · doi:10.3390/cancers10100384 · Cited by 9
Wu, Z., Liu, X., Yan, X.-E., Wu, X., Huang, W., Li, J., Xiu, Y., Lv, C., Sun, C., Wang, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01320 · Cited by 8
High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
Takahashi, T., Terazono, H., Suetsugu, T., Sugawara, H., Arima, J., Nitta, M., Tanabe, T., Okutsu, K., Ikeda, R., Mizuno, K., et al. (2021) · Cancers · doi:10.3390/cancers13143425 · Cited by 8
PCM1: A Potential Prognostic Biomarker Correlated with Immune Infiltration in Lung Adenocarcinoma
Guo, Z., Liang, J., Zhang, X., Ai, Q., Xie, Z., Zhao, H., Wu, F., Tan, Z., Yin, W., & Ji, L. (2023) · Current Proteomics · doi:10.2174/0115701646270898231123065507 · Cited by 8
Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling
Bissegger, L., Constantin, T. A., Keleş, E., Raguž, L., Barlow-Busch, I., Orbegozo, C., Schaefer, T., Borlandelli, V., Bohnacker, T., Sriramaratnam, R., et al. (2024) · Chemical Science · doi:10.1039/d4sc05459h · Cited by 9
Melosky, B. L., Popat, S., & Gandara, D. R. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.019 · Cited by 8
Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 8
Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer
Lamparella, N. E., Barochia, A., & Almokadem, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_6 · Cited by 8
Carnio, S., Novello, S., Bironzo, P., & Scagliotti, G. V. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.949245 · Cited by 7
Tyrosine kinase inhibitors as first-line treatment in NSCLC
Maemondo, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30055-9 · Cited by 8
Xinmin, Z., Wan, X., Xu, J. H., Wang, H., Chen, H., Zeng, Q., Zhang, W., & Zhao, B. (2020) · Aging · doi:10.18632/aging.103066 · Cited by 8
Hu, X., Wu, J., He, Q., Xiong, Z., & Li, N. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101045 · Cited by 8
Xie, Z., Chen, X., Gao, R., Yang, M., Han, X., Sun, Y., & Shi, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004016 · Cited by 8
Self-citationEGFR Inhibitors as the First-Line Systemic Treatment for Advanced Non-Small-Cell Lung Cancer
Kao, H., Lin, C., & Yang, J. C. (2013) · Future Oncology · doi:10.2217/fon.13.56 · Cited by 7
Self-citationTreatment Advances in Lung Cancer with Leptomeningeal Metastasis
Meng, Y., Zhu, M., Yang, J., Wang, X., Liang, Y., Yu, M., Li, L., & Kong, F. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096276133231201061114 · Cited by 8
Self-citationThe Diagnosis and Treatment of Brain Metastases in EGFR Mutant Lung Cancer
Minchom, A. R., Yu, K. C., Bhosle, J., & O’Brien, M. (2014) · CNS Oncology · doi:10.2217/cns.14.19 · Cited by 7
The role of afatinib in the management of non-small cell lung carcinoma
Yap, T. A., & Popat, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.832755 · Cited by 7
Köhler, J., & Schüler, M. (2014) · Future Oncology · doi:10.2217/fon.14.9 · Cited by 7
Hu, X., Han, X., Yang, S., Li, N., Wang, L. Q., Song, Y., Mu, H., & Shi, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189626 · Cited by 7
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Hoo, W. P. Y., Siak, P. Y., & In, L. L. A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190904163524 · Cited by 7
Sheng‐Kai, K., Lo, J., Chodosh, J., & Dana, R. (2024) · The Ocular Surface · doi:10.1016/j.jtos.2024.03.008 · Cited by 7
Pilz, M. J., Seyringer, S., Al-Naesan, I., King, M. T., Bottomley, A., Norman, R., Schlosser, L., Hell, T., Gamper, E., & the EORTC Quality of Life Group (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00484-9 · Cited by 7
Hall, P. E., Spicer, J. F., & Popat, S. (2015) · Future Oncology · doi:10.2217/fon.15.110 · Cited by 7
Peters, M. J., Bowden, J. J., Carpenter, P., Lewis, J., & Solomon, B. (2014) · Internal Medicine Journal · doi:10.1111/imj.12449 · Cited by 7
Targeted Therapy and New Anticancer Drugs in Advanced Disease
Silva, S., & Danson, S. J. (2013) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2013.05.008 · Cited by 7
EGFr, FGFr and PDGFr: Emerging Targets for Anticancer Drug Design
Nandi, S., & Bagchi, M. C. (2016) · Journal of cancer research updates · doi:10.6000/1929-2279.2016.05.03.3 · Cited by 7
Mitsudomi, T., & Kobayashi, Y. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.06 · Cited by 7
Spicer, J. F., Irshad, S., Ang, J. E., Enting, D., Kristeleit, R. S., Uttenreuther‐Fischer, M., Pemberton, K., Pelling, K., Schnell, D., & Bono, J. S. D. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3189-1 · Cited by 7
Li, Y., Liu, Y., Ying, X., Zhou, H., Wang, Z., Wu, S., Yan, J., Jing, Y., & Yang, Y. (2017) · Biotechnology Progress · doi:10.1002/btpr.2564 · Cited by 7
Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
Nishimura, Y., & Itoh, K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.15 · Cited by 7
Demircan, N. C., Telli, T. A., Başoğlu, T., Arıkan, R., Kocakaya, D., Şahin, A. A., Erçelep, Ö., Dane, F., & Yumuk, P. F. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100594 · Cited by 7
The significance of plasma high density lipoprotein cholesterol (hdlc).
Gupta, S., & Rajagopal, G. (2007) · PubMed · Cited by 7
Wu, J., Yu, L., Li, K., Zhang, D., Ye, L., Xu, X., Zhou, J., Li, Z., & Xu, H. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c01173 · Cited by 6
Nath, R., Baishya, S., Nath, D., Nahar, L., Sarker, S. D., Choudhury, M. D., & Talukdar, A. D. (2023) · Phytochemical Analysis · doi:10.1002/pca.3254 · Cited by 6
Araki, T., Kanda, S., Komatsu, M., Sonehara, K., Tateishi, K., Takada, M., Kato, A., Yamamoto, M., Nishie, K., Hama, M., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-12 · Cited by 6
Hu, S., Jiang, C., Gao, M. Q., Zhang, D., Yao, N., Zhang, J., & Jin, Q. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137224 · Cited by 6
Advances in Small-molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-cancer Agents
Kang, J.-X., Li, C., Cheng, Y.-M., Huang, M.-X., Zhao, G.-K., Jin, Z., Qi, X., Gu, J., & Ouyang, Q. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673308896240528173317 · Cited by 6
Merk, D. J., Tsiami, F., Hirsch, S., Walter, B., Haeusser, L. A., Maile, J. D., Stahl, A., Jarboui, M. A., Lechado‐Terradas, A., Klose, F., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03438-w · Cited by 6
First-Line Therapeutic Options for Advanced Non-Small-Cell Lung Cancer in the Molecular Medicine Era
Capelletto, E., Novello, S., & Scagliotti, G. V. (2014) · Future Oncology · doi:10.2217/fon.13.247 · Cited by 6
Qi, W., Fu, S., Zhang, Q., & Guo, X. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000230 · Cited by 6
Approach to Biomarker Testing: Perspectives from Various Specialties
Sung, M., Ellis, P. M., Verma, S., Duncan, E., & Leighl, N. B. (2016) · Current Oncology · doi:10.3747/co.23.3019 · Cited by 6
Kashiwabara, K., Semba, H., Fujii, S., & Tsumura, S. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.06.007 · Cited by 6
Roller, D. G., Hoang, S. A., Rawls, K. D., Owen, K. A., Simmers, M. B., Figler, R. A., Wulfkuhle, J. D., Petricoin, E. F., Wamhoff, B. R., & Gioeli, D. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-84612-z · Cited by 6
Yamada, Y., Imai, H., Sugiyama, T., Minemura, H., Kanazawa, K., Kasai, T., Minato, K., Kaira, K., & Kaburagi, T. (2021) · Medicina · doi:10.3390/medicina57090929 · Cited by 6
Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
Palermos, D., Sergentanis, T. Ν., Gavriatopoulou, M., Malandrakis, P., Ψαλτοπούλου, Θ., Terpos, E., & Ntanasis‐Stathopoulos, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237176 · Cited by 6
Evaluating the efficacy and cardiotoxicity of EGFR-TKI AC0010 with a novel multifunctional biosensor
Jiang, D., Wei, X., Zhu, Y., Qiu, Y. L., Liu, X., Kong, L., Li, F., Liu, J., Zhuang, L., Wan, H., et al. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-023-00493-4 · Cited by 6
Wei, Y., Shen, K., Lv, T., Wang, X., Li, C., Fan, H., Lv, Y., Liu, H., & Song, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.028 · Cited by 6
Nishimura, T., Okano, T., Naito, M., Iwanaka, S., Ohiwa, A., Sakakura, Y., Yasuma, T., Fujimoto, H., D’Alessandro‐Gabazza, C. N., Oomoto, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13870 · Cited by 6
Targeted Therapies for Non-Small Cell Lung Cancer
Russo, A. D., Rolfo, C. D., Passiglia, F., & Rosell, R. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_9 · Cited by 6
Metabolic disorders associated with the use of targeted cancer therapies
Kotecki, N., Penel, N., & Awada, A. H. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000176 · Cited by 6
Metadata
- Authors
- Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, E.-H., Chao, T.-Y., Shahidi, M., Cong, X. J., Lorence, R. M., & Yang, J. C.-H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- McGill University Health Centre (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Taipei Veterans General Hospital (TW)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Tongji University (CN)
- National Cheng Kung University Hospital (TW)
- Peking Union Medical College Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Seoul National University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- National Taiwan University (TW)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 13
- Issue
- 5
- Pages
- 528-538
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152905269
- Cited by
- 961
- References
- 29
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 28 · 2023: 38 · 2022: 33 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 70 · 2017: 103 · 2016: 99 · 2015: 125 · 2014: 139 · 2013: 107 · 2012: 37
- FWCI
- 105.26
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-05-01)
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, non-small cell lung cancer, lung adenocarcinoma, EGFR tyrosine kinase inhibitors, erlotinib, gefitinib, EGFR mutation, EGFR inhibitor resistance, second-line therapy, overall survival, progression-free survival, best supportive care, targeted therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Afatinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
